Bipolar RF Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue and Effect on Elastin

Skin Laxity Clinical Trial

Official title:

Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Lift of the Submental and Neck Tissue

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04245696
• Other study ID #: PFD19002
• Status: Withdrawn
• Phase: N/A
• Start date: March 9, 2020
• Est. completion date: August 5, 2021

Study information

• Verified date: August 2021
• Source: Candela Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being conducted to evaluate the safety and efficacy of bipolar fractional radiofrequency treatment via use of the Profound System to achieve lift in lax submental (beneath the chin) and neck tissue

Description:

A multi-center, blinded, non-randomized, non-controlled study

Up to 60 eligible participants will be enrolled at up to three (3) sites. Participants will receive one (1) treatment in the submental/neck area. Participants will complete follow-up visits for clinical evaluation at Day 14, 1 Month, 3 Month, and 6 Months after the study treatment. Standard photography will be obtained at Screening to the 6 Month follow-up, and 3D photography will be obtained at Screening, Month 3, and Month 6 visit.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 5, 2021
• Est. primary completion date: August 5, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• Healthy male and female adults between ages 21-70 years of age.

• Desire skin laxity lift of submental and neck regions.

• Confirmed BMI = 35.

• Subjects who can read, understand, and sign the Informed Consent Form.

• Subjects willing and able to comply with all study requirements.

• Fitzpatrick skin type I-VI.

• Submental fat graded by the Investigator as = 1 using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS, 0=Absent (No localized submental fat evidence), 4=Extreme (Extreme submental convexity)

Exclusion Criteria:

• Active localized or systemic infections, that may alter wound healing.

• Immunocompromised subjects.

• Subjects with coagulation disorder.

• History of skin photosensitivity disorders, or use of photosensitizing drugs (e.g., tetracycline or sulfa drugs).

• Pregnant and/or lactating (All female volunteers will be advised about using birth control during the period of study).

• Excessive skin laxity on the submental and neck (Submental Skin Laxity Grade: SMSLG 4=Severe, superficial wrinkling present), or other anatomical feature for which reduction in submental fat (SMF) which may, in the judgment of the investigator, result in an aesthetically unacceptable outcome.

• Scarring in areas to be treated.

• Tattoos in the treatment areas to be treated.

• Significant open facial wounds or lesions.

• Severe or cystic acne in treatment areas.

• Current active smoker.

• Use of Accutane (Isotretinoin) within the past 6 months.

• Use of topical retinoids within 48 hours.

• Use of prescription anticoagulants.

• Pacemaker or internal defibrillator.

• History of skin disorders resulting in abnormal wound healing (i.e. keloids, extreme dry and fragile skin).

• Subjects on current oral corticosteroid therapy or within the past 6 months

• Metal implants in the treatment area.

• In the opinion of the investigator, subject is unwilling or unable to adhere to all study requirements, including application and follow-up visits.

• Subjects with a history of radiation therapy to the treatment area.

• Subject has a history of allergy to lidocaine or ester-based local anesthetics.

• Subjects with significant cardiac history or rhythm disturbance who may be unable to tolerate lidocaine with epinephrine.

• Subjects with any skin pathology or condition in the treatment area that could interfere with evaluation or with the use of typical ancillary medical treatments or care used before, during or after treatments (e.g. psoriasis, rosacea, eczema, seborrheic dermatitis, vitiligo, hyper or hypo-skin pigmentation conditions such as post inflammatory hyperpigmentation).

• Subjects who are unwilling to shave excessive hair in the treatment area that might influence or impair evaluation in the opinion of the Investigator.

• Subjects have undergone skin resurfacing or tightening treatments in the treatment area over the past year.

• Subjects have undergone dermatological treatments such as fillers and neurotoxins for the past 6 months in the treatment area.

• Subjects have undergone laser and light treatments in the treatment area over the past 3 months.

• Subjects have undergone superficial peel or microdermabrasion within 4 weeks.

Related Conditions & MeSH terms

• Cutis Laxa
• Skin Laxity

Intervention

Device:
• Dermal Handpiece / SubQ Handpiece
Bipolar radiofrequency (RF) travels from the RF generator, through the electrodes and into the dermal layers beneath the surface of the skin. The microneedles of the Dermal and SubQ cartridges coupled with thermal heat will stimulate neocollagenesis and neoelastosis, aiding in the reduction of submental laxity.

Locations

Country	Name	City	State
United States	Candela Institute of Excellence	Marlborough	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Candela Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in submental skin laxity	Improvement in overall lifting of treated tissue in the submental/neck region via blinded evaluation of Baseline (pre-procedure) and Day 180 (post-procedure) photographs	Baseline - Day 180 (6 months post-treatment)
Primary	Occurrence, severity, and relatedness of adverse events	The number and level of severity of adverse events after device treatment. An assessment will also be made to determine if the adverse event is related to the study devices and/or procedure	Baseline - Day 180 (6 months post-treatment)
Secondary	Change in submental skin laxity	Improvement in overall lifting of treated tissue in the submental/neck region via blinded evaluation of Baseline (pre-procedure) and Day 90 (post-procedure) photographs	Baseline - Day 90 (3 months post-treatment)
Secondary	Surface Area Assessment to demonstrate percentage of participants having improvement in tissue lift (> 20mm2 in submental and neck skin laxity)	Change in submental and neck skin laxity via 3D photo-analysis	Baseline vs. Day 180
Secondary	Subject assessment of improvement in skin laxity	Improvement in skin laxity scored by subject using a 5-point Global Aesthetic Improvement Score (1=Very Much Improved, 5=Worse)	3 Month Follow-Up and 6 Month Follow-Up
Secondary	Subject satisfaction of treatment results: Subject Satisfaction scale	Using a Subject Satisfaction scale, subjects will score satisfaction of treatment results (1=Not Satisfied, 5=Very Satisfied). Lower scores will show worse outcomes and higher scores will show better outcomes.	Day 14 - 6 Month Follow-Up
Secondary	Subject assessment of pain: Numerical Pain Rating Scale	The subjects' assessment of pain will be completed using an 11-point Numerical Pain Rating Scale (0=No pain, 10=extreme pain)	Treatment Visit